SAN DIEGO, March 21, 2017 /PRNewswire/ -- OncoSec
Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company
developing DNA-based intratumoral cancer immunotherapies, today
presented a poster titled "Intratumoral Electroporation-mediated
IL-12 Gene Therapy Can Enhance Tumor Immunogenicity" (Poster
#2074), at the Keystone Symposia Conference, "Cancer Immunology and
Immunotherapy: Taking a Place in Mainstream Oncology," in
Whistler, British Columbia,
Canada. The poster included preclinical data demonstrating that in
vivo electroporation of intratumoral plasmid IL-12
(ImmunoPulse® IL-12) enhances immunogenicity in poorly
immunogenic mouse cancer models. For more information
about this meeting, please visit http://keystonesymposia.org.
"These data support the hypothesis that intratumoral delivery of
plasmid IL-12 with electroporation can alter the tumor's immune
environment in such a way that a 'cold' non-immunogenic tumor is
converted to a 'hot' immunogenic tumor, thus further supporting
recent clinical data that ImmunoPulse IL-12 is a rational
combination therapy with anti-PD-1 checkpoint therapies," said
Punit Dhillon, President and CEO.
"Also, generation of an antigen-specific CD8 T-cell response
provides evidence for a potential mechanism of action for the
abscopal responses seen in both preclinical and clinical
settings."
The full-text abstract is available on the Publications section
of OncoSec's website (www.oncosec.com).
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology,
ImmunoPulse®, for the treatment of cancer. ImmunoPulse®
is designed to enhance the local delivery and uptake of DNA-based
immune-targeting agents, such as IL-12. In Phase I and II clinical
trials, ImmunoPulse® IL-12 has demonstrated a
favorable safety profile and evidence of anti-tumor activity in the
treatment of various solid tumors as well as a systemic immune
response. OncoSec's lead program,
ImmunoPulse® IL-12, is currently in clinical
development for metastatic melanoma and triple-negative breast
cancer. The program's current focus is on the significant unmet
medical need in patients with melanoma who are refractory or
non-responsive to anti-PD-1/PD-L1 therapies. In addition to
ImmunoPulse® IL-12, the Company is also identifying
and developing new immune-targeting agents for use with the
ImmunoPulse® platform. For more information, please
visit www.oncosec.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements can be
identified by words such as "can," "may," "will," "suggest," "look
forward to," "potential," "understand," and similar references to
future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based on
management's current preliminary expectations and are subject to
risks and uncertainties, which may cause our results to differ
materially and adversely from the statements contained herein.
Potential risks and uncertainties that could cause actual results
to differ from those predicted include, among others, the
following: uncertainties inherent in pre-clinical studies and
clinical trials, such as the ability to enroll patients in clinical
trials and the risk of adverse events; unexpected new data, safety
and technical issues; our ability to raise additional funding
necessary to fund continued operations; and the other factors
discussed in OncoSec's filings with the Securities and Exchange
Commission.
Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
disclaims any obligation to update any forward-looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events.
CONTACT:
Investor Relations
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Media
Laura Radocaj
DGI Comm
212-825-3210
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-medicals-intratumoral-plasmid-il-12-demonstrates-effectiveness-at-enhancing-tumor-immunogenicity-in-preclinical-tumor-models-300427139.html
SOURCE OncoSec Medical Incorporated